Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
225Ac-PSMA-62
/
Eli Lilly
Welcome,
Profile
Billing
Logout
Diseases
Trials
Trials
News
||||||||||
225Ac-PSMA-62
/
Eli Lilly
First in human evaluation of PSMA-62: Intraindividual comparison of [Ga-68]-PSMA-62 and [Ga-68]-PMSA-11 PET/CT in patients with mCRPC
(714B (Convention Center); In-Person) - May 8, 2024 - Abstract #SNMMI2024SNMMI_2253;
In addition, [Ga-68]-PSMA-62 has significantly lower salivary gland uptake relative to [Ga-68]-PSMA-11. These preliminary clinical data with [Ga-68]-PSMA-62 are encouraging and suggest that therapy with [Ac-225]-PSMA-62 may lead to reduced incidence and severity of xerostomia relative to currently available PSMA directed radioligands.